Birth length is the strongest predictor of linear growth status and stunting in the first 2 years of life after a preconception maternal nutrition intervention: the children of the Women First trial

• Published in: The American journal of clinical nutrition Vol. 116; no. 1; pp. 86 - 96
• Main Authors: Krebs, Nancy F, Hambidge, K Michael, Westcott, Jamie L, Garcés, Ana L, Figueroa, Lester, Tshefu, Antoinette K, Lokangaka, Adrien L, Goudar, Shivaprasad S, Dhaded, Sangappa M, Saleem, Sarah, Ali, Sumera Aziz, Bauserman, Melissa S, Derman, Richard J, Goldenberg, Robert L, Das, Abhik, Chowdhury, Dhuly
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2022; Oxford University Press; American Society for Clinical Nutrition, Inc
• Subjects: Anthropometry; Birth; birth length; breastfeeding; Child; Chronology; Dietary Supplements; Editor's Choice; Female; Gestational Age; growth; Growth Disorders - prevention & control; Human nutrition; Humans; Infant; infant growth; Infant, Newborn; Infants; maternal height; Maternal Nutritional Physiological Phenomena; Nutrition; Original Research Communications; preconception; Pregnancy; stunting; SES; preconception; LAZ; WLZ; DCC; maternal height; GEE; SGA; stunting; SQ-LNS; WF; WAZ; birth length; DRC; LWB; growth; infant growth; breastfeeding; IG; HVRA
• ISSN: 0002-9165; 1938-3207
• DOI: 10.1093/ajcn/nqac051

The multicountry Women First trial demonstrated that nutritional supplementation initiated prior to conception (arm 1) or early pregnancy (arm 2) and continued until delivery resulted in significantly greater length at birth and 6 mo compared with infants in the control arm (arm 3). We evaluated intervention effects on infants’ longitudinal growth trajectory from birth through 24 mo and identified predictors of length status and stunting at 24 mo. Infants’ anthropometry was obtained at 6, 12, 18, and 24 mo after the Women First trial (registered at clinicaltrials.gov as NCT01883193), which was conducted in low-resource settings: Democratic Republic of Congo, Guatemala, India, and Pakistan. Longitudinal models evaluated intervention effects on infants’ growth trajectory from birth to 24 mo, with additional modeling used to identify adjusted predictors for growth trajectories and outcomes at 24 mo. Data for 2337 (95% of original live births) infants were evaluated. At 24 mo, stunting rates were 62.8%, 64.8%, and 66.3% for arms 1, 2, and 3, respectively (NS). For the length-for-age z-score (LAZ) trajectory, treatment arm was a significant predictor, with adjusted mean differences of 0.19 SD (95% CI: 0.08, 0.30; P < 0.001) and 0.17 SD (95% CI: 0.07, 0.27; P < 0.001) for arms 1 and 2, respectively. The strongest predictors of LAZ at 24 mo were birth LAZ <–2 and <–1 to ≥–2, with adjusted mean differences of –0.76 SD (95% CI: –0.93, –0.58; P < 0.001) and –0.47 SD (95% CI: –0.56, –0.38; P < 0.001), respectively. For infants with ultrasound-determined gestational age (n = 1329), the strongest predictors of stunting were birth LAZ <–2 and <–1 to ≥– 2: adjusted relative risk of 1.62 (95% CI: 1.39, 1.88; P < 0.001) and 1.46 (95% CI: 1.31, 1.62; P < 0.001), respectively. Substantial improvements in postnatal growth are likely to depend on improved intrauterine growth, especially during early pregnancy.